RPRX Form 4: Christopher Hite reports 3,696 award shares; 70,000 shares disposed

Rhea-AI Filing Summary

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc (RPRX), reported insider transactions on Form 4. The filing records an exempt acquisition of 3,696 Class A ordinary shares on 08/06/2025 in connection with the settlement of Equity Performance Awards under Rule 16b-3, recorded with a price of $0. The form also shows a reported disposition of 70,000 Class A ordinary shares (marked as a sale).

After the reported activity, the total beneficial ownership is reported as 652,342 shares, held indirectly through SCH Investment Partners LLC. The filing was signed by an attorney-in-fact on behalf of Mr. Hite.

Positive

• Exempt acquisition of 3,696 shares via Rule 16b-3 shows compensation alignment through equity awards
• Substantial reported beneficial ownership: 652,342 shares held indirectly via SCH Investment Partners LLC

Negative

• Disposition of 70,000 shares is reported, representing insider selling that may prompt investor questions about liquidity or timing
• Sale size relative to the disclosed holdings could be considered notable and may warrant monitoring in subsequent filings

Insights

Financial Analyst

TL;DR: Routine insider award settlement plus a significant sale reported; overall ownership remains sizeable at 652,342 shares.

The Form 4 records two routine types of insider activity: an exempt award settlement acquisition of 3,696 shares and a reported disposition of 70,000 shares. The acquisition is exempt under Rule 16b-3 and shows a $0 price, consistent with equity award settlement rather than an open-market purchase. The post-transaction beneficial ownership is listed as 652,342 shares, held indirectly via SCH Investment Partners LLC, indicating continued meaningful exposure despite the disposition. The combination of award vesting and sale is common in executive compensation cycles and requires context (e.g., size relative to holdings and timing) to assess impact on incentives and liquidity needs.

Corporate Governance Expert

TL;DR: Transaction mix appears procedural: equity award settlement and insider sale; disclosure is standard and identifies indirect ownership vehicle.

The filing clearly attributes ownership to SCH Investment Partners LLC, which is useful for governance transparency. The exempt acquisition of 3,696 shares under Rule 16b-3 reflects internal compensation settlement practices and is disclosed appropriately. The reported 70,000-share disposition is a material-sized sale relative to common executive trades and should be noted by stakeholders reviewing insider liquidity and governance signals. Overall, disclosures conform to Section 16 requirements and describe the nature of indirect beneficial ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hite Christopher

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Vice Chairman

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	08/06/2025		A		3,696(1)	A	$0	652,342	I	By SCH Investment Partners LLC
Class A Ordinary Shares								70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Christopher Hite report on Form 4 for RPRX?

The Form 4 reports an exempt acquisition of 3,696 Class A ordinary shares and a reported disposition of 70,000 Class A ordinary shares.

When was the acquisition of shares recorded on the Form 4?

The acquisition is recorded with a transaction date of 08/06/2025 and is described as a settlement of Equity Performance Awards under Rule 16b-3.

What price is shown for the acquisition of the 3,696 shares?

The acquisition is recorded with a price of $0, consistent with settlement of equity awards rather than a cash purchase.

How many Royalty Pharma shares does the filing show beneficially owned after the transactions?

The filing reports 652,342 shares beneficially owned following the reported transaction(s), held indirectly via SCH Investment Partners LLC.

What is the reporting person's role at Royalty Pharma?

The reporting person, Christopher Hite, is identified as EVP & Vice Chairman of Royalty Pharma plc.